A New Test for Heparin-Induced Thrombocytopenia (HIT)
Official title: An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia
Funded at Retham Technologies, INC. · NIH-11043284 · Data updated 2026-11-12
This project is developing a more accurate and faster blood test to identify patients who have a serious reaction to heparin, called Heparin-induced Thrombocytopenia (HIT).
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Retham Technologies, INC. NIH-funded |
| Lab location | 1 site (Wauwatosa, UNITED STATES) |
| Project start | June 15, 2019 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,154,002 |
| NIH project number | 2R44HL147734-04 |
| Project ID | NIH-11043284 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is relevant for patients who are treated with heparin and are suspected of having Heparin-induced Thrombocytopenia (HIT).
✕Less likely to help
Patients who are not receiving heparin or do not have symptoms of HIT would not directly benefit from this specific diagnostic test.
What this research studies
Heparin-induced Thrombocytopenia (HIT) is a severe reaction to heparin that can be life-threatening. Current tests for HIT are often either not very accurate, leading to unnecessary treatments, or they take too long to provide results. This new test aims to quickly and precisely identify the specific antibodies in your blood that cause HIT. By doing so, it could help doctors make faster, more informed decisions about your care, avoiding delays or treatments you don't need.
Why it matters
Potential benefit: If successful, this new diagnostic test could lead to earlier and more accurate diagnosis of HIT, preventing serious complications and improving patient outcomes.
How similar studies have gone: While current HIT tests have limitations, this project builds on findings that specific platelet treatments can improve the sensitivity and specificity of antibody detection.
Where this research is happening
-
Retham Technologies, INC.
Wauwatosa, United States Active
Researchers
- Principal investigator: Jones, Curtis — Retham Technologies, INC.
- Study coordinator: Jones, Curtis
Related research
Other NIH-funded projects on the same topics.
-
A faster, more accurate test for HIT antibodies
A new in vitro diagnostic test aims to quickly and accurately detect harmful antibodies linked to heparin-induced thrombocytopenia in patients who need help deciding on treatment.
-
Developing a test to detect harmful antibodies related to Heparin-induced Thrombocytopenia
This study is working on a new, more accurate test to help doctors find out if patients have Heparin-induced Thrombocytopenia (HIT), a serious condition that can happen when they receive heparin treatment, so that patients can get the right care without the confusion of false-positive results from current tests.
-
Developing a test to detect harmful antibodies related to Heparin-induced Thrombocytopenia
This study is working on a new, more accurate test to help doctors find out if patients have Heparin-induced Thrombocytopenia (HIT), a serious condition that can happen when they receive heparin treatment, so that patients can get the right care and feel better faster.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.